NASDAQ · ZVRA
Zevra Therapeutics, Inc.
$10.21-$0.15 (-1.45%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.2% below the high.
Loading market information…
NASDAQ · SPPI · USD
Stock price, dividends, earnings
Quote as of Jul 31, 2023, 07:56 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Spectrum Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Spectrum Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Spectrum Pharmaceuticals, Inc. operates as a biopharmaceutical firm, primarily engaged in the research, development, and market introduction of innovative drug products for cancer and blood disorders. Its robust pipeline features Eflapegrastim, an advanced, long-acting granulocyte colony-stimulating factor designed to address chemotherapy-induced neutropenia. Also under development is Poziotinib, a distinct irreversible tyrosine kinase inhibitor intended for non-small cell lung cancer tumors exhibiting various mutations. Furthermore, Anti-CD20-IFNa, an antibody-interferon fusion molecule targeting CD20, is progressing through Phase I development for patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. The company maintains key collaborative agreements, such as co-development, commercialization, and in-licensing arrangements with Hanmi Pharmaceutical Co. Ltd., a patent and technology license with The University of Texas M.D. Anderson Cancer Center, and an in-license pact with ImmunGene, Inc. Founded in 1987, and initially known as NeoTherapeutics, Inc. before its name change in December 2002, Spectrum Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 17, 2022 |
| -$0.26-23.81% vs estimate |
| $0.06 |
| Q3 2021 | Nov 10, 2021 | -$0.21+30.0% vs estimate | $0.00 |
|---|
KEEP COMPARING
$10.21-$0.15 (-1.45%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.2% below the high.
$4.00+$0.01 (+0.25%)
Inozyme Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 35.9% below the high.
$5.38-$0.01 (-0.09%)
Third Harmonic Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.42% below the high.
$2.27$0.00 (0.0%)
Acelyrin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$4.47$0.00 (0.0%)
CARGO Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 82.44% below the high.
$5.00+$0.51 (+11.36%)
Vaccitech plc’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
$4.07+$0.01 (+0.12%)
Theseus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.14% below the high.
$3.33-$0.17 (-4.73%)
LENZ Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.65% below the high.
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
